Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial
X
Xiaowei Zhang
T
Ting Zhao
M
Midie Xu
Y
Yanjing Guo
Q
Qifeng Wang
Y
Yanli Wang
L
Liangping Zhou
S
Silong Hu
Q
Qinghua Xu
(College of Energy Materials and Chemistry)
X
Xichun Hu
(Shanghai Cancer Center, Fudan University, Shanghai, China)
X
Xin Liu
Z
Zhiguo Luo
Article Details
Journal
Nature Communications
Volume / Issue
Vol. 17, Issue 1
Published
May 09, 2026
ISSN
2041-1723
Publisher
Nature Portfolio
Authors (12)
X
Xiaowei Zhang
T
Ting Zhao
M
Midie Xu
Y
Yanjing Guo
Q
Qifeng Wang
Y
Yanli Wang
L
Liangping Zhou
S
Silong Hu
Q
Qinghua Xu
College of Energy Materials and Chemistry
X
Xichun Hu
Shanghai Cancer Center, Fudan University, Shanghai, China
X
Xin Liu
Z
Zhiguo Luo
Related Articles from this Journal
Synthesis of adaptive 15N-nitrosyl-Co7 nanocluster for electrocatalytic C–H functionalization
Chao Wu, Xu Zhang et al.
Aug 2026
10.1038/s41467-026-76516-1
Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses
Connor Weidle, Natalie Brunette et al.
Aug 2026
10.1038/s41467-026-76114-1
Multi-population GWAS meta-analysis identifies bladder cancer susceptibility loci and highlights genetic regulation of smoking-related risk
Ludmila Prokunina-Olsson, Oscar Florez-Vargas et al.
Aug 2026
10.1038/s41467-026-76157-4
Genome-wide annotation of human multi-nucleotide variants reveals widespread functional differences from single nucleotide variants
Weiwei Jin, Wen Cao et al.
Aug 2026
10.1038/s41467-026-76470-y
Allele-specific chromatin architecture shapes imprinted domains and coordinates a distal enhancer and antisense transcription at the mouse Mest-Copg2 domain
Bongmin Bae, Katherine Gu et al.
Aug 2026
10.1038/s41467-026-76506-3